,-Lactamase assays and inhibition studies. P-Lactamases used for analysis of the stability of tigemonam were partially purified enzymes, as previously described (5). Stability against P-lactamases was determined by using a computerized, heat-controlled spectrophotometer (Response; Gilford Instrument Laboratories, Inc., Oberlin, Ohio). The change in the absorbance of each substrate at its absorption maximum at a 0.1 mM concentration was monitored. Inhibition assays were done with equimolar concentrations of cephaloridine and tigemonam. Enzymes were preincubated with tigemonam for 10 min at 35°C before cephaloridine was added to the mixture.
The discovery in 1978 of the monobactam antibiotics led to the discovery of a new family of beta-lactam agents. Aztreonam, the first of these agents, has undergone extensive in vitro, pharmacological, and clinical studies and recently has been approved for clinical use in the United States (1, 4, 7, (12) (13) (14) (15) . Other monobactam agents have been synthesized, and carumonam is also currently undergoing clinical investigation in Japan and the United States. Although several monobactams have been shown to be absorbed after oral ingestion in rodents, tigemonam is the first monobactam which is absorbed well after oral administration in both laboratory animals and humans (3, 16 Tigemonam was more active than aztreonam against Klebsiella oxytoca, Enterobacter spp., and Citrobacterfreundii, but with other species aztreonam usually was more active by one dilution. Tigemonam did not inhibit Pseudomonas aeruginosa but was more active than aztreonam against Pseudomonas cepacia and, like aztreonam, tigemonam did not inhibit Acinetobacter spp.
Tigemonam was considerably more active than cephalexin and amoxicillin-clavulanate in inhibiting members of the family Enterobacteriaceae resistant to both agents. Tigemonam also inhibited E. coli and Klebsiella, Proteus, Providencia, and Serratia spp. resistant to trimethoprim-sulfamethoxazole (TMP-SMX). It also inhibited Salmonella and Shigella spp. resistant to amoxicillin, TMP-SMX, and chloramphenicol (data not shown). Klebsiella spp., most Enterobacter spp., and S. marcescens isolates resistant to gentamicin were inhibited by <2 ,ug of tigemonam per ml. Similar to the MICs of virtually all other new betalactams, tigemonam MICs for some Enterobacter cloacae and C. freundii isolates were 8 to 16 ,ug/ml. For these same isolates, cefotaxime, ceftazidime, and cefoperazone MICs were .32 ,ug/ml, but the isolates were inhibited by 4 pg of imipenem per ml (data not shown). Overall, ciprofloxacin, the quinolone used for comparison, was more active than any of the other agents tested by 32-to 128-fold.
The activity of tigemonam against gram-positive and anaerobic bacteria is shown in Table 2 . It had virtually no activity against staphylococci, but hemolytic streptococci were inhibited at concentrations of 1 to 16 ,ug/ml, as compared with 16 to >128 ,ug of aztreonam per ml. The same was true for Streptococcus pneumoniae and Clostridium perfringens, but Streptococcus faecalis, viridans group streptococci, Listeria monocytogenes, and Bacteroides fragilis were completely resistant to tigemonam, as they were to aztreonam.
Effect of growth conditions upon MICs and MBCs. The in vitro activity of tigemonam was similar in Mueller-Hinton, brain heart infusion, and tryptic digest agar media for the members of the family Enterobacteriaceae tested (five isolates each of E. coli, Klebsiella pneumoniae, S. marcescens, Providencia stuartii, and Enterobacter spp.). Tigemonam MBCs were two-to fourfold higher than the MICs, except for P. mirabilis (Table 3) , and in general the MBCs werp <2 ,ug/ml. All of the isolates tested were ampicillin and cephalexin resistant. The effect of variation of the inoculum size is shown in Table 4 . The MICs were slightly lower at 103 CFU than at 105 CFU, and at 107 CFU the MICs increased from -0.12 to .4 ,ug/ml for K. pneumoniae and Morganella morganii.
The activity of tigemonam in urine and human serum <1.6 x 10-10 <1.6 x 10-1 appreciably hydrolyzed by the important plasmid 13-lacKlebsiella pneumoniae 104 <1.7 x 10-10 <1.7 x lo-10 tamases TEM-1, TEM-2, and SHV-1, (Table 7) . These same 5. There also was minimal hydrolysis of tigemonam by the against representative isolates of three species is shown in important chromosomal P-lactamase of E. cloacae (P99), the Table 5 . The MBC in serum was two-to fourfold higher than C. freundii P-lactamase, or the inducible chromosomal 1- that in pH 7.4 Mueller-Hinton broth; the MBC in urine was lactamase of P. aeruginosa (Sabath-Abraham enzyme). Plasequal to or twofold higher than that in pH 7.4 broth. mid 1-lactamases of B. catarrhalis and Staphylococcus Activity of tigemonam against permeability mutants. The aureus and chromosomal ,B-lactamases of Bacteroides fraactivity of tigemonam against various E. coli mutants with gilis did not hydrolyze tigemonam. altered outer membrane proteins was determined. TigemoThe ,B-lactamase-inhibiting activity of tigemonam is shown nam was more active by two-, four-, or eightfold against the in Table 8 . Tigemonam, like aminothiazole cephalosporins, mutants than it was against the parent strain, E. coli was a poor inhibitor of the common plasmid 1-lactamase UB1005. Against these same strains the MICs of a drug such TEM-1, but it was an effective inhibitor of chromosomal as cephaloridine showed no differences; the MICs of cefof3-lactamases such as E. cloacae P99 and the P. aeruginosa taxime (6; data not shown) were also four-to eightfold lower Sabath-Abraham enzyme. In this sense, it was similar to for the mutants.
aztreonam and cefotaxime and unlike clavulanate. The Ki of Frequency of spontaneous single-step resistance to tigemotigemonam for TEM-1 was 50.8 ,uM, as compared with a Ki nam. For E. coli, K. pneumoniae, and S. marcescens, the of 0.86 ,uM for P99. The ,B-lactamase-inducing ability of tigemonam was examined for single isolates of E. cloacae, S. marcescens, and C. freundii. Tigemonam was not an active inducer of P-lactamases in these species (Table 9 ), which had previously been shown to have P-lactamases inducible by cefoxitin and other beta-lactams (6) . No reduction of the zone size of piperacillin or cefamandole was found for E. cloacae when tested with a disk containing tigemonam.
DISCUSSION
The monobactams are a new family in the class of betalactam antibiotics. Although it has been possible to synthesize monocyclic beta-lactams with activity against many different bacteria, most of the compounds which have been developed inhibit aerobic gram-negative bacteria. Aztreonam has undergone extensive clinical investigation (4, 12, 13) and is currently used in the United States, Europe, and Japan to treat gram-negative infections of the respiratory and urinary tracts and gynecological and intra-abdominal infections.
No oral monobactams were available before tigemonam. As this study shows, tigemonam has in vitro activity similar to that of aztreonam, with the notable exception that it fails to inhibit P. aeruginosa. This result is related to the moiety on the ,-acyl side chain which does not produce the antipseudomonas activity of the iminopropyl carboxyl moiety of aztreonam. The iminocarboxy substituent, however, does provide tigemonam with some activity against gram-positive aerobic hemolytic streptococci, even though this activity i § much lower than that of penicillins or cephalosporins. The two methyl groups at position 4 provide tigemonam with greater stability against attack by the K-1 3-lactamase of K. oxytoca. We previously showed that a ,-methyl compound similar to aztreonam was more active against bacteria pOs sessing the K-1 P-lactamase (8) . In this study tigemonam hai activity against enteric organisms resistant to cephalexidi, amoxicillin-clavulanate, and even TMP-SMX. It also inhib.
ited selected gentamicin-resistant members of the family Enterobacteriaceae at concentrations of s2 ,ug/ml. (11) , and it is probable that tigemonam will be similar. Further studies of the pharmacology and clinical efficacy of this agent will determine its role in clinical infections.
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